...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury
【24h】

Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury

机译:使用维拉帕米减轻糖尿病视网膜病变和胰腺损伤的抑制硫氧嘧啶相互作用蛋白和炎症组件

获取原文
获取原文并翻译 | 示例
           

摘要

It has been previously demonstrated by our group that genetic inhibition of thioredoxin-interacting-protein (TXNIP) preserved retinal neuronal function in chemically-induced retinopathy. Moreover, elevated intracellular levels of TXNIP and calcium ions play important roles in hyperglycemia-induced oxidative stress and inflammation. Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy. Diabetic retinopathy was assessed in type-1 diabetes rat model induced by a single intravenous injection of streptozotocin (45 mg/kg), with or without daily treatment with verapamil (10 mg/kg, oral) for 4 months. Verapamil treatment commenced 48 h post-streptozotocin insult and continued for 16 weeks. Untreated diabetic rats exhibited higher expression of toll-like-receptor-4 (TLR4), TXNIP, nucleotide-binding domain-like receptor protein-3 (NLRP3), caspase-1, cytochrome-c, and ssDNA as assessed immunohistochemically in both retinal and pancreatic tissues 16 weeks post-diabetes induction. This was associated with a reduced thioredoxin reductase (Trx-R) activity, increased release of TNF-alpha and IL-113 into vitreous fluid along with retinal ganglion cell (RGC) loss, pancreatic islets shrinkage, and enhanced CD34 expression. The treatment with verapamil enhanced Trx-R activity, significantly inhibited TLR4 mediated NLRP3-inflammasome assembly with subsequent diminishing of inflammatory markers (TNF-alpha and IL-113) release into the vitreous, suppression of pathological angiogenesis, and preservation of RGC count and pancreatic islets diameter. Current study showed that using the calcium channel blocker, verapamil, interferes with the pathogenesis of diabetic retinopathy and pancreatic islets damage at multiple levels mainly through the inhibition of TLR4, TXNIP and NLRP3-inflammasome, suggesting its promising role as an anti-diabetic and a neuroprotective agent.
机译:我们的研究小组之前已经证明,硫氧还蛋白相互作用蛋白(TXNIP)的基因抑制在化学诱导的视网膜病变中保留了视网膜神经元功能。此外,TXNIP和钙离子的细胞内水平升高在高血糖诱导的氧化应激和炎症中起重要作用。目前的研究旨在评估使用维拉帕米药物抑制TXNIP治疗糖尿病视网膜病变的潜在疗效。在单次静脉注射链脲佐菌素(45 mg/kg)诱导的1型糖尿病大鼠模型中,评估糖尿病视网膜病变,并使用或不使用维拉帕米(10 mg/kg,口服)每日治疗4个月。维拉帕米治疗在链脲佐菌素损伤后48小时开始,持续16周。糖尿病诱导16周后,未经治疗的糖尿病大鼠视网膜和胰腺组织中toll-like-receptor-4(TLR4)、TXNIP、核苷酸结合域样受体蛋白-3(NLRP3)、caspase-1、细胞色素c和ssDNA的表达均较高。这与硫氧还蛋白还原酶(Trx-R)活性降低、TNF-α和IL-113释放增加、视网膜神经节细胞(RGC)丢失、胰岛萎缩和CD34表达增强有关。维拉帕米治疗可增强Trx-R活性,显著抑制TLR4介导的NLRP3炎性体组装,随后减少炎性标记物(TNF-α和IL-113)向玻璃体的释放,抑制病理性血管生成,并保留RGC计数和胰岛直径。目前的研究表明,钙通道阻滞剂维拉帕米主要通过抑制TLR4、TXNIP和NLRP3炎性体,在多个水平上干预糖尿病视网膜病变和胰岛损伤的发病机制,表明其作为抗糖尿病和神经保护剂的前景。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号